Clinical Study: African Mango (IGOB131®)

Study 1: Significant Weight Loss Over a Ten Week Period

The breakthrough and most quoted African Mango study is the one that was published in the Lipids In Health and Disease Journal on March 2nd, 2009. Here is the information:

  • Methods: The study participants comprised of 102 healthy, overweight and/or obese volunteers (defined as BMI > 25 kg/m2) were randomly divided into two groups. The groups received on a daily basis, either 150 mg of IGOB131 or matching placebo in a double blinded fashion, 30–60 minutes before lunch and dinner. At baseline, 4, 8 and 10 weeks of the study, subjects were evaluated for changes in anthropometrics and metabolic parameters to include fasting lipids, blood glucose,
    C-reactive protein, adiponectin, and leptin.
  • Results: Significant improvements in body weight, body fat, and waist circumference as well as plasma total cholesterol, LDL cholesterol, blood glucose, C-reactive protein, adiponectin and leptin levels were observed in the IGOB131 group compared with the placebo group.
  • Conclusion: Irvingia Gabonensis administered 150 mg twice daily before meals to overweight and/or obese human volunteers favorably impacts body weight and a variety of parameters characteristic of the metabolic syndrome. This is the first double blind randomized placebo controlled clinical trial regarding the anti-obesity and lipid profile modulating effects of an Irvingia Gabonensis extract. The positive clinical results, together with our previously published mechanisms of gene expression modulation related to key metabolic pathways in lipid metabolism, provide impetus for much larger clinical studies. Irvingia Gabonensis extract may prove to be a useful tool in dealing with the emerging global epidemics of obesity, hyperlipidemia, insulin resistance, and their co-morbid conditions.
Source: Lipids in Health and Disease, March 2nd 2009

Study 2: The Effects of a Higher Dosage of IGOB131
on Cholesterol Levels

A second study, also done in the Journal of Lipids of Health and Disease, looked at the effects of a larger dosage of IGOB131 on cholesterol levels. In this study, one group of subjects were given 350mg of IGOB131, three times a day for four weeks. A control group was given a placebo. Here are the results:

  • Results: Effect on blood lipids components The plasma total cholesterol concentration was reduced by 39.21%, triglyerides by 44.9% (p < 0,05) and LDL by 45.58%. This was accompanied by a significant increase in HDL-cholesterol of 46.852%. The CT/HDL ratio (p < 0.05) and the blood glucose level were also reduced (32.36%; p < 0.05). No significant change was observed in the placebo group.
Source: Lipids in Health and Disease, May 25th 2005

Important African Mango Information